The arrival of four new astronauts as part of the Crew 12 mission—Jessica Meir and Jack Hathaway of NASA, Sophie Adenot of the European Space Agency, and Andrey Fedyaev of Roscosmos—brought the total ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...

Struggling with email open rates? These 10 AI-powered subject line generator tools—like Omnisend, Coschedule, and Mailmeteor—help craft catchy, relevant lines in seconds. Whether you’re cold-emailing, ...

Even when the intention is to express equality, speech can still reinforce gender stereotypes, because biases can slip through via subtle linguistic cues. For example, a subject-complement statement ...

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

While the chef is busy dealing with an oven that’s on the fritz, it’s up to you to put together the pairings for tonight’s nine-course menu. Every clue below has a one-word answer; as a hint, the ...

K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma. This is an ASCO Meeting ...